Publications

by | March 2, 2015 | Uncategorized

European Medicines Agency – Draft Proposal on Transparency Addendum

In a recent public consultation, the European Medicines Agency (EMA) solicited stakeholders’ views about its draft proposal for a transparency addendum pertaining to the content of the EU portal and database that will be set up for the implementation of the Clinical Trial Regulation No 536/2014. The express aim of the latter is to provide more information on clinical trials and their result in Europe.

The consultation on the ’Draft proposal for an addendum, on transparency, to the ’Functional specifications for the EU portal and EU database to be audited – EMA/42176/2014’, which ran from ? The consultation on the ’ Draft proposal for an addendum , on transparency , to the ’ Functional specifications for the EU portal and EU database to be audited – EMA/42176/2014 ’, which ran from 21 January to 18 February 2015, brought to light a number of important transparency-related questions, notably regarding the nature and scope of what may or may not be classified as ’commercially confident information’ (CCI).

EPHA would also like to recall that we generally support the key points brought forward by the ‘All Trials Campaign’ which means that all trials should be registered and all results reported (click here to see their response to the consultation). That being said, there are differences in how EPHA members gauge the scope of view CCI – e.g. and these might be linked to whether or not organisations are themselves actively involved in clinical trials or not .g. related to the nature of the organisations’ role in the clinical trials process.

—-
The following consultation points were flagged by EPHA members:
——

– EMA’s definition of CCI needs to be narrowed down. Regulation 1049/2001 regarding public access to European Parliament, Council and Commission documents stipulates that confidentiality is exceptional (i.e. transparency is the norm!) and cannot apply whenever there is an overriding public interest in disclosure.

– The consideration of what might be CCI should be based on the nature of the trial and not on who is sponsoring it (e.g. academic and non-commercial actors).

– The list of clinical trials’ clinical investigators and their sites should be made public as part of the authorisation, including the CVs of the principal investigators, their economic interests and institutional affiliations.

– The database should also provide the contact details of the investigator site as this would help trial participants, carers and health professionals to obtain more detailed information and also allow the promotion of trial opportunities to potential participants. Researchers might wish to find answers to scientific questions or data.

– Any delays in making information public must be justified and subject to independent audit; they must be thoroughly checked against public health and patient safety interests.

– More clarity would be welcomed on how the concept of ’overriding public interest’ could be applied and decisions on CCI be challenged.

– Sponsors should not have the option to defer publication of documents related to Phase IV and low-intervention trials: information pertaining to authorised trials is very useful to patients and health professionals (e.g., risks and benefits of current treatments) and it also frequently involves research on off-label use.

– Regarding the ’triggers for timing of publication’ for products without a marketing authorisation, a ten-year delay following the conclusion of a trial is a long period for gaining access to protocols and other information on the main characteristics of a trial; further clarification would be needed as to why this period was chosen.

Some EPHA members considered that such a delay could compromise the scientific benefits of transparency as in the interim period investigations might be conducted that would otherwise have been better informed by earlier disclosure of such trial information.

– More information is required regarding the composition, nomination process and role of the EU expert group foreseen to develop guidance on clinical study reports submitted by the marketing-authorisation applicant/holder

Get the EPHA Newsletter

The best of our activities, right in your inbox!